SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

6322684

Reference Type

Journal Article

Title

SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

Author(s)

Kaufman, PA; Pipas, M; Finn, GJ; Mathews, SE; Zhang, H; Richards, J; Kudla, AJ; Bloom, T; Zalutskaya, AA; Llorin-Sangalang, J; Pinto, AnaC; Ettl, J

Year

2018

Is Peer Reviewed?

Yes

Journal

Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445

Volume

Issue

Web of Science Id

WOS:000425489400120